Advanced search
1 file | 849.87 KB Add to list

Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model

(2021) ALLERGY. 76(4). p.1041-1052
Author
Organization
Abstract
The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.

Downloads

  • (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • PDF
    • |
    • 849.87 KB

Citation

Please use this url to cite or link to this publication:

MLA
Incorvaia, Cristoforo, et al. “Personalized Medicine for Allergy Treatment : Allergen Immunotherapy Still a Unique and Unmatched Model.” ALLERGY, vol. 76, no. 4, 2021, pp. 1041–52, doi:10.1111/all.14575.
APA
Incorvaia, C., Al-Ahmad, M., Ansotegui, I. J., Arasi, S., Bachert, C., Bos, C., … Canonica, G. W. (2021). Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model. ALLERGY, 76(4), 1041–1052. https://doi.org/10.1111/all.14575
Chicago author-date
Incorvaia, Cristoforo, Mona Al-Ahmad, Ignacio J. Ansotegui, Stefania Arasi, Claus Bachert, Catherine Bos, Jean Bousquet, et al. 2021. “Personalized Medicine for Allergy Treatment : Allergen Immunotherapy Still a Unique and Unmatched Model.” ALLERGY 76 (4): 1041–52. https://doi.org/10.1111/all.14575.
Chicago author-date (all authors)
Incorvaia, Cristoforo, Mona Al-Ahmad, Ignacio J. Ansotegui, Stefania Arasi, Claus Bachert, Catherine Bos, Jean Bousquet, Andrzej Bozek, Davide Caimmi, Moises A. Calderon, Thomas Casale, Adnan Custovic, Frederic De Blay, Pascal Demoly, Philippe Devillier, Alain Didier, Alessandro Fiocchi, Adam T. Fox, Philippe Gevaert, Maximiliano Gomez, Enrico Heffler, Natalia Ilina, Carla Irani, Marek Jutel, Efstrathios Karagiannis, Ludger Klimek, Piotr Kuna, Robin O’Hehir, Oxana Kurbacheva, Paolo M. Matricardi, Mario Morais-Almeida, Ralph Mosges, Natalija Novak, Yoshitaka Okamoto, Petr Panzner, Nikolaos G. Papadopoulos, Hae-Sim Park, Giovanni Passalacqua, Ruby Pawankar, Oliver Pfaar, Peter Schmid-Grendelmeier, Silvia Scurati, Miguel Tortajada-Girbes, Carmen Vidal, J. Christian Virchow, Ulrich Wahn, Margitta Worm, Petra Zieglmayer, and Giorgio W. Canonica. 2021. “Personalized Medicine for Allergy Treatment : Allergen Immunotherapy Still a Unique and Unmatched Model.” ALLERGY 76 (4): 1041–1052. doi:10.1111/all.14575.
Vancouver
1.
Incorvaia C, Al-Ahmad M, Ansotegui IJ, Arasi S, Bachert C, Bos C, et al. Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model. ALLERGY. 2021;76(4):1041–52.
IEEE
[1]
C. Incorvaia et al., “Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model,” ALLERGY, vol. 76, no. 4, pp. 1041–1052, 2021.
@article{8693230,
  abstract     = {{The introduction of personalized medicine (PM) has been a milestone in the history of medical therapy, because it has revolutionized the previous approach of treating the disease with that of treating the patient. It is known today that diseases can occur in different genetic variants, making specific treatments of proven efficacy necessary for a given endotype. Allergic diseases are particularly suitable for PM, because they meet the therapeutic success requirements, including a known molecular mechanism of the disease, a diagnostic tool for such disease, and a treatment blocking the mechanism. The stakes of PM in allergic patients are molecular diagnostics, to detect specific IgE to single-allergen molecules and to distinguish the causative molecules from those merely cross-reactive, pursuit of patient's treatable traits addressing genetic, phenotypic, and psychosocial features, and omics, such as proteomics, epi-genomics, metabolomics, and breathomics, to forecast patient's responsiveness to therapies, to detect biomarker and mediators, and to verify the disease control. This new approach has already improved the precision of allergy diagnosis and is likely to significantly increase, through the higher performance achieved with the personalized treatment, the effectiveness of allergen immunotherapy by enhancing its already known and unique characteristics of treatment that acts on the causes.}},
  author       = {{Incorvaia, Cristoforo and Al-Ahmad, Mona and Ansotegui, Ignacio J. and Arasi, Stefania and Bachert, Claus and Bos, Catherine and Bousquet, Jean and Bozek, Andrzej and Caimmi, Davide and Calderon, Moises A. and Casale, Thomas and Custovic, Adnan and De Blay, Frederic and Demoly, Pascal and Devillier, Philippe and Didier, Alain and Fiocchi, Alessandro and Fox, Adam T. and Gevaert, Philippe and Gomez, Maximiliano and Heffler, Enrico and Ilina, Natalia and Irani, Carla and Jutel, Marek and Karagiannis, Efstrathios and Klimek, Ludger and Kuna, Piotr and O'Hehir, Robin and Kurbacheva, Oxana and Matricardi, Paolo M. and Morais-Almeida, Mario and Mosges, Ralph and Novak, Natalija and Okamoto, Yoshitaka and Panzner, Petr and Papadopoulos, Nikolaos G. and Park, Hae-Sim and Passalacqua, Giovanni and Pawankar, Ruby and Pfaar, Oliver and Schmid-Grendelmeier, Peter and Scurati, Silvia and Tortajada-Girbes, Miguel and Vidal, Carmen and Virchow, J. Christian and Wahn, Ulrich and Worm, Margitta and Zieglmayer, Petra and Canonica, Giorgio W.}},
  issn         = {{0105-4538}},
  journal      = {{ALLERGY}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{1041--1052}},
  title        = {{Personalized medicine for allergy treatment : allergen immunotherapy still a unique and unmatched model}},
  url          = {{http://dx.doi.org/10.1111/all.14575}},
  volume       = {{76}},
  year         = {{2021}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: